237 related articles for article (PubMed ID: 30720056)
1. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
[TBL] [Abstract][Full Text] [Related]
2. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
3. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
McKnight BN; Kim S; Boerner JL; Viola NT
Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells.
Li X; Xu L; Li H; Zhao L; Luo Y; Zhu Z; Liu Y; Qu X
Mol Med Rep; 2015 Jun; 11(6):4547-54. PubMed ID: 25625229
[TBL] [Abstract][Full Text] [Related]
7. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
8. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
12. Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.
Shin M; Yang EG; Song HK; Jeon H
BMB Rep; 2015 Jun; 48(6):342-7. PubMed ID: 25341922
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
14. SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells.
Xu KP; Yin J; Yu FS
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2832-9. PubMed ID: 16799022
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
[TBL] [Abstract][Full Text] [Related]
16. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
17. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.
Darmoul D; Gratio V; Devaud H; Peiretti F; Laburthe M
Mol Cancer Res; 2004 Sep; 2(9):514-22. PubMed ID: 15383630
[TBL] [Abstract][Full Text] [Related]
18. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17.
Maretzky T; Evers A; Zhou W; Swendeman SL; Wong PM; Rafii S; Reiss K; Blobel CP
Nat Commun; 2011; 2():229. PubMed ID: 21407195
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
